<DOC>
	<DOCNO>NCT00944333</DOCNO>
	<brief_summary>Prospective , randomize , non-inferiority , multicenter , international study.In total 4000 patient ( 70 center Europe ) de novo lesion native coronary artery meet eligibility criterion randomize 6 versus 12 month dual antiplatelet therapy follow second generation DES implantation . Assuming true proportion thrombotic event equal 2.3 % regimen ( 6-month 12-month clopidogrel ) 2000 patient treatment group necessary demonstrate non-inferiority 6-months regimen proportion thrombotic event 3.5 % power 0.80 significance level 0.05 ( one-tail ) . If non-inferiority hypothesis reject , superiority hypothesis ( 12-months regimen superior 6-months-regimen ) test significance level 0.05 ( two-tails ) . The maximal clinically relevant difference non-inferiority hypothesis 1.2 % thrombotic event consider together low expect number bleed event 6-months regimen . All analysis do `` intention-to-treat '' analysis .</brief_summary>
	<brief_title>Second Generation '' Drug-Eluting Stents Implantation Followed Six Versus Twelve-Month - Dual Antiplatelet Therapy</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) OR unstable angina pectoris ( Braunwald Classification B &amp; C , IIIIII ) OR patient document silent ischemia , treat second generation drug elute stent Presence one de novo stenosis equal great 70 % native coronary artery , treat Resolute drug elute stent Patient &gt; 18 year age ( minimum age require local regulation ) . The patient consent participate signing `` Patient Informed Consent Form '' '' The patient willing able cooperate study procedure require follow visit Any type lesion number lesion include trial unless specifically detailed exclusion criterion . At least one second generation DES implant target lesion last 24 hour No DES implant target procedure No BMS implant 12 month target procedure Patients treat lesion venous arterial graft Patients treat instent restenosis Patients treat Unprotected Left Main lesion ST elevation myocardial infarction 48 hour prior procedure Non ST elevation myocardial infarction Patients LVEFâ‰¤30 % Women know pregnancy lactate Patients hypersensitivity allergy hepari , analogue derivative , cobalt , chromium , nickel , molybdenum contrast medium . Patients chronic renal insufficiency Contraindication use clopidogrel and/or ASA : History drug allergy thienopyridine derivative ASA History clinically significant persistent thrombocytopenia neutropenia Active bleed significant risk bleeding , elderly patient receining fibrinolytic therapy potent antithrombotic agent , severe hepatic insufficiency , current peptic ulceration , proliferative diabetic retinopathy Uncontrolled hypertension Current medical condition life expectancy le 24 month . The subject participate another device drug study Subject must complete followup phase previous study least 30 day prior enrolment trial . Patients medical condition preclude followup define protocol otherwise limit participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>second generation DES</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>dual platelet therapy</keyword>
	<keyword>patient document silent ischemia</keyword>
	<keyword>unstable angina pectoris ( Braunwald Classification )</keyword>
	<keyword>Diagnosis angina pectoris ( CCS )</keyword>
</DOC>